Novo Nordisk A/S is a Danish pharmaceutical company that researches, manufactures, and distributes medications through two main divisions: one focused on obesity, diabetes, cardiovascular conditions, and related therapies, and another serving rare blood disorders, rare endocrine conditions, and hormone replacement needs. The company produces insulin delivery devices, glucose management applications, growth hormone treatments, and oral weight management medications, while also collaborating with Anthropic on artificial intelligence applications in drug development. It operates globally across Europe, Asia, the Americas, and Africa.

entry readiness 59 · MODERATE · exit proximity 0

Value area 41.10–49.04 · 64% of 120d volume overhead · heavy supply